Selumetinib (a selective MEK inhibitor) and dabrafenib (a selective BRAF inhibitor used in BRAF-mutated tumors) have been shown to increase RAI uptake by RAI-refractory tumor tissues68,69, and these encouraging results are now under investigation (NCT02393690 and NCT03244956). This evidence concerns the gene BRAF and neoplasm.